Exchange: NASDAQ·Updated 07:54 PM EST

OPK Earnings

Latest Earnings Results: Q3 '26

Reported: Nov 04

Estimated EPS

-$0.07

Reported EPS

-$0.05

Surprise

+26.47%

Estimated Rev

$136.62M

Reported Rev

$65.4M

Surprise

-52.13%

• Reported GAAP EPS of -$0.07 down -333.33% YoY • Reported revenue of $65.4M down -56.88% YoY

Bullish Takeaway

OPKO Health's Global Products segment returned to operating income as revenue rose; Regeneron collaboration offers potential milestone payments, while the Labcorp agreement includes $722M cash consideration plus contingent 4Kscore proceeds.

Bearish Takeaway

OPKO Health continued operating cash outflows and reports no history of sustained positive cash flow; Innovative Biotech losses widened amid higher development spending; BioReference liabilities remain after sale, pending approvals.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.07
--
--
N/A
Q3 '26
-$0.07
-$0.05
26.47%
BEAT
Q2 '26
-$0.08
-$0.01
87.50%
BEAT
Q1 '26
-$0.07
-$0.07
--
EXPECTED
Q4 '25
-$0.07
-$0.04
41.67%
BEAT

Advertisement|Remove ads.